The Claim
In patients with homozygous familial hypercholesterolemia (HoFH), the median duration of PCSK9 inhibitor treatment was 12.0 months (IQR 4.0–19.1), suggesting sustained clinical use despite limited LDL-C reduction, which may reflect real-world clinical inertia in discontinuing ineffective therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People with a rare cholesterol condition stayed on a pricey cholesterol drug for about a year on average, even though it didn’t help much — doctors might just keep prescribing it because they’re hesitant to stop treatments that aren’t working.
See the scientific wording
The median duration of PCSK9 inhibitor treatment in patients with homozygous familial hypercholesterolemia (HoFH) was 12.0 months (IQR 4.0–19.1), indicating sustained use despite limited LDL-C lowering, which may reflect real-world clinical inertia in discontinuing ineffective therapy.
What the research says
1 studyThe study found that patients kept taking PCSK9 drugs for about a year even though the drugs didn’t lower bad cholesterol much, which supports the idea that doctors may keep prescribing them even when they’re not working well.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.